secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0000950170-23-005714
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.
- Net loss Q4 2022 $38.8M ($0.74/share) vs $51.8M ($1.00/share) in Q4 2021; full year net loss $168.1M ($3.23/share).
- R&D expenses FY2022 $142.8M, up from $121.3M in FY2021; G&A expenses $28.2M vs $28.7M.
- Enrollment continues in ACHIEVE (DYNE-101 in DM1) and DELIVER (DYNE-251 in DMD) Phase 1/2 registrational trials.
- Initial data from MAD placebo-controlled portions of both trials anticipated in second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/dyn-20230302.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer